Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck Kgaa ADR
(OP:
MKKGY
)
38.44
+0.05 (+0.13%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck Kgaa ADR
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
December 12, 2023
Pfizer Inc (NYSE: PFE)
Via
Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
December 06, 2023
Merck KGaA (OTC: MKGAF) (OTC:
Via
Benzinga
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
September 26, 2023
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.
Via
Benzinga
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
August 03, 2023
Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported
Via
Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
July 26, 2023
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen
Via
Benzinga
Germany's Merck To Launch Semiconductor Base In China
May 31, 2022
Via
Benzinga
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
June 20, 2023
RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,
Via
Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
April 18, 2023
Via
Benzinga
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
April 12, 2023
Via
Benzinga
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
March 27, 2023
Via
Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
Via
Benzinga
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
January 20, 2023
Via
Benzinga
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
January 03, 2023
Via
Benzinga
Mersana Inks Cancer Therapy Development Deal With Merck Germany
December 23, 2022
Via
Benzinga
SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19
October 19, 2022
Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger
Via
Benzinga
Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug
October 19, 2022
The French court is reportedly investigating Germany-based Merck KGaA (OTC: MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox.
Via
Benzinga
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers
October 11, 2022
Via
Benzinga
TSM Looks To Hire Over 8,000 People In 2022
January 24, 2022
Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge, Financial...
Via
Benzinga
Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing
January 21, 2022
Amid continued questions about the profitability and the competitive advantages of Palantir in a crowded field, PLTR stock remains a sell.
Via
InvestorPlace
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
November 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...
Via
Benzinga
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
September 30, 2021
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said...
Via
Benzinga
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
September 21, 2021
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE...
Via
Benzinga
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
August 24, 2021
Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the...
Via
Benzinga
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
June 01, 2021
Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA...
Via
Benzinga
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
June 01, 2021
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT...
Via
Benzinga
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
May 14, 2021
Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript
May 13, 2021
MKKGY earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
May 10, 2021
England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as...
Via
Benzinga
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
April 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc...
Via
Benzinga
Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
April 07, 2021
Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.